Hosted on MSN9d
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
clinicaladvisor.com9d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Hosted on MSN4d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
FOX40 News29d
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SNB-101 is an innovative anticancer drug, marking the world's first nanoparticle formulation of SN-38, the active metabolite ... conjugates (ADCs) such as Enhertu® and Trodelvy®.
Nasdaq11d
FDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast Cancer
(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...
Monthly Prescribing Reference11d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has approved Enhertu ® (fam ...
Taiwan News28d
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SNB-101 is an innovative anticancer drug, marking the world's first nanoparticle formulation of SN-38, the active metabolite of irinotecan ... its use in drug-antibody conjugates (ADCs) such as ...